OBJECTIVES: Human Cell Division Cycle 20 (CDC20) homolog is a crucial target of the spindle assembly checkpoint. It is an activator of the Anaphase-Promoting Complex/Cyclosome (APC/C) which promotes anaphase onset and mitotic exit through the ubiquitination of securin and cyclin B1. Overexpression of CDC20 was previously reported in oral squamous cell carcinoma (OSCC). Here, we propose to explore the clinicopathological significance of CDC20 overexpression and its potential use as a prognostic marker in OSCC. METHODS: Using tissue microarray technology, we analyzed CDC20 expression in 65 primary OSCC tissues by immunohistochemistry. Statistical analysis was performed to evaluate the clinicopathological and prognostic significance of CDC20 expression in OSCC. RESULTS: Of the 65 cases of patients with OSCC studied, 37 (56.9%) showed high CDC20 protein expression. No clinicopathological features were correlated with CDC20 expression. Importantly, in univariable analysis, OSCC patients with higher CDC20 protein expression showed significantly shorter cancer-specific survival rate (P = 0.018). Multivariable analysis identified high CDC20 expression as an independent prognostic factor (P = 0.032). CONCLUSION: High CDC20 expression is associated with poor prognosis in OSCC and may be used to identify high-risk OSCC patients and may serve as a therapeutic target.
OBJECTIVES:HumanCell Division Cycle 20 (CDC20) homolog is a crucial target of the spindle assembly checkpoint. It is an activator of the Anaphase-Promoting Complex/Cyclosome (APC/C) which promotes anaphase onset and mitotic exit through the ubiquitination of securin and cyclin B1. Overexpression of CDC20 was previously reported in oral squamous cell carcinoma (OSCC). Here, we propose to explore the clinicopathological significance of CDC20 overexpression and its potential use as a prognostic marker in OSCC. METHODS: Using tissue microarray technology, we analyzed CDC20 expression in 65 primary OSCC tissues by immunohistochemistry. Statistical analysis was performed to evaluate the clinicopathological and prognostic significance of CDC20 expression in OSCC. RESULTS: Of the 65 cases of patients with OSCC studied, 37 (56.9%) showed high CDC20 protein expression. No clinicopathological features were correlated with CDC20 expression. Importantly, in univariable analysis, OSCC patients with higher CDC20 protein expression showed significantly shorter cancer-specific survival rate (P = 0.018). Multivariable analysis identified high CDC20 expression as an independent prognostic factor (P = 0.032). CONCLUSION: High CDC20 expression is associated with poor prognosis in OSCC and may be used to identify high-risk OSCC patients and may serve as a therapeutic target.
Authors: Hai Huang; Qin Zhang; Chen Ye; Jian-Min Lv; Xi Liu; Lu Chen; Hao Wu; Lei Yin; Xin-Gang Cui; Dan-Feng Xu; Wen-Hui Liu Journal: J Cancer Res Clin Oncol Date: 2017-08-28 Impact factor: 4.553
Authors: Ilkka Heikkinen; Alhadi Almangush; Jaana Hagström; Ibrahim O Bello; Joonas H Kauppila; Laura K Mäkinen; Caj Haglund; Pentti Nieminen; Tuula Salo; Ilmo Leivo Journal: Eur Arch Otorhinolaryngol Date: 2016-04-18 Impact factor: 2.503
Authors: Mariana F Gayyed; Nehad M R Abd El-Maqsoud; Ehab Rifat Tawfiek; Saad Abdelnaby A El Gelany; Mohamed Fathy Abdel Rahman Journal: Tumour Biol Date: 2015-08-06
Authors: H Karra; H Repo; I Ahonen; E Löyttyniemi; R Pitkänen; M Lintunen; T Kuopio; M Söderström; P Kronqvist Journal: Br J Cancer Date: 2014-05-22 Impact factor: 7.640
Authors: Susanne Lub; Anke Maes; Ken Maes; Kim De Veirman; Elke De Bruyne; Eline Menu; Karel Fostier; Alboukadel Kassambara; Jérôme Moreaux; Dirk Hose; Xavier Leleu; Randall W King; Karin Vanderkerken; Els Van Valckenborgh Journal: Oncotarget Date: 2016-01-26